Motif Bio PLC Issue of Equity (7265T)
January 09 2017 - 11:28AM
UK Regulatory
TIDMMTFB
RNS Number : 7265T
Motif Bio PLC
09 January 2017
Motif Bio plc
("Motif Bio" or the "Company")
Issue of Equity and Total Voting Rights
Motif Bio plc (AIM: MTFB) the clinical stage biopharmaceutical
company specialising in developing novel antibiotics announces that
it has issued 143,700 new ordinary shares in the Company ("Ordinary
Shares") as a result of the exercise of options.
Application has been made for the 143,700 new Ordinary Shares to
be admitted to trading on AIM ("Admission"), which is expected to
occur at 8.00 a.m. on 13 January 2017. The new Ordinary Shares will
rank pari passu with the existing Ordinary Shares. Following
Admission, and for the purposes of the Disclosure and Transparency
Rules, the Company's total issued share capital will consist of
195,885,228 Ordinary Shares. Shareholders may use this figure as
the denominator for the calculations by which they will determine
if they are required to notify their interest in, or a change to
their interest in, the issued share capital of the Company.
For further information please contact:
Motif Bio plc info@motifbio.com
Graham Lumsden (Chief
Executive Officer)
Zeus Capital Limited (NOMAD
& BROKER)
Phil Walker/Giles Balleny
Dominic Wilson +44 (0)20 3829 5000
Northland Capital Partners
Limited (BROKER)
Patrick Claridge/ David
Hignell
John Howes/ Rob Rees (Broking) +44 (0)20 3861 6625
Walbrook PR Ltd. (FINANCIAL +44 (0)20 7933 8780 or motifbio@walbrookpr.com
PR & IR) Mob: +44 (0)7980 541 893
Paul McManus Mob: +44 (0)7900 608 002
Mike Wort
MC Services AG (EUROPEAN
IR)
Raimund Gabriel +49 (0)89 210 2280
About Motif Bio plc www.motifbio.com
Motif Bio is a clinical-stage biopharmaceutical company, engaged
in the research and development of novel antibiotics designed to be
effective against serious and life-threatening infections in
hospitalised patients caused by multi-drug resistant bacteria. Our
lead product candidate, iclaprim, is being developed for the
treatment of acute bacterial skin and skin structure infections
(ABSSSI) and hospital acquired bacterial pneumonia (HABP),
including ventilator associated bacterial pneumonia (VABP), which
is often caused by MRSA (methicillin resistant Staphylococcus
aureus). We are currently enrolling and dosing patients in two
global Phase 3 clinical trials (Revive 1 and Revive 2) with an
intravenous formulation of iclaprim, for the treatment of ABSSSI.
Data readout for REVIVE-1 is expected in the second quarter of 2017
and REVIVE-2 is on track for data readout in the second half of
2017.
This information is provided by RNS
The company news service from the London Stock Exchange
END
IOEUGUMPGUPMGMB
(END) Dow Jones Newswires
January 09, 2017 12:28 ET (17:28 GMT)
Motif Bio (LSE:MTFB)
Historical Stock Chart
From Apr 2024 to May 2024
Motif Bio (LSE:MTFB)
Historical Stock Chart
From May 2023 to May 2024